AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Maria M. Perotin
Jun. 28--With brisk sales in the United States and overseas, eye-care giant Alcon saw growth across its stable of products last year.
The Fort Worth-based company enjoyed gains from its introduction of a new ear-infection drug and the latest version of its AcrySof intraocular lenses, used to treat cataracts. All told, revenue climbed to $3.4 billion for the maker of ophthalmic surgery equipment, prescription drugs and consumer eye-care products.
Alcon's return on equity of 46.4 percent was especially strong, surpassing all but one company on the list. And income grew 114.5 percent, ranking Alcon No. 7 in that category.
It was a strong showing for the decades-old company, which went public in March 2002 and debuted last year at No. 2 on the All-Stars list.